Asahi shares mark weekly slide after cyberattack halts production
Investing.com - Benchmark raised its price target on XOMA, Ltd. (NASDAQ:XOMA) to $50.00 from $35.00 on Tuesday, while maintaining a Buy rating on the stock. The company’s shares, currently trading at $35.60, are near their 52-week high of $36.32, having delivered an impressive 62% return over the past six months. According to InvestingPro analysis, XOMA is currently trading at Fair Value.
The price target increase follows XOMA shares reaching Benchmark’s previous $35 target, bolstered by strong second-quarter 2025 earnings and several recent merger and acquisition transactions. The company’s financial health appears solid, with a current ratio of 4.88 indicating strong liquidity, while revenue growth reached nearly 195% in the last twelve months. InvestingPro subscribers can access 11 additional key insights about XOMA’s financial performance.
XOMA recently completed the acquisition of publicly-traded Mural Oncology, adding to three other transactions that closed after the end of the second quarter.
These earlier acquisitions included Turnstone Biologics, LAVA Therapeutics, and HilleVax, representing a significant expansion of XOMA’s portfolio through M&A activity.
Benchmark cited the strong Q2 2025 earnings report as a key factor in its decision to raise the price target for the royalty-focused biotech company.
In other recent news, XOMA, Ltd. reported strong financial results for the second quarter of 2025, with revenue reaching $13.1 million, surpassing Leerink Partners’ estimate of $10.4 million by 29%. The company’s GAAP earnings per share stood at $0.44, significantly exceeding the analyst’s prediction of -$0.07. Leerink Partners has reiterated its Outperform rating on XOMA with a price target of $55.00. In addition, XOMA Royalty Corporation has announced separate acquisition agreements with HilleVax, Inc. and LAVA Therapeutics N.V. The deal with HilleVax involves a cash payment of $1.95 per share, along with a contingent value right (CVR) for potential additional payments. Similarly, the acquisition of LAVA Therapeutics will include a cash payment between $1.16 and $1.24 per share, plus a CVR representing 75% of net proceeds from LAVA’s partnered assets. H.C. Wainwright has maintained its Buy rating on XOMA, setting a price target of $104.00, citing the company’s diverse business model. These developments highlight XOMA’s strategic efforts to expand its royalty portfolio and engage in acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.